16 February 2022
TREATT PLC
(“Treatt” or “the Group”)
Appointment of Chief Financial Officer
Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, announces that Ryan Govender will join the Company as CFO – Designate on 23rd May 2022. After a handover period to ensure a smooth transition, Ryan will replace Richard Hope as CFO and an Executive Director on the Board on 1st July 2022 . As announced previously, Richard will be retiring on 30 June 2022.
Ryan is an experienced CFO, having worked for over 20 years in senior finance roles across global FMCG businesses, particularly in the food sector. His diverse experience includes strategy, FP&A, corporate structuring, large capital projects, investor relations and finance transformation.
For the past 12 years he has been working at Associated British Foods, the FTSE 100 international food, ingredients and retail group, most recently as CFO of SPI Pharma, a provider of innovative solutions to global pharmaceutical and nutritional customers. Before that he held finance and management roles within other ABF businesses, including Speedibake, Germains Seed Technology and Illovo Sugar. He qualified as a Chartered Accountant at PwC in South Africa.
Daemmon Reeve, CEO of Treatt, commented:
“It's fantastic to have Ryan joining our team at Treatt. His significant international experience in FMCG businesses will be extremely valuable, as we continue to benefit from a number of prevailing consumer trends across our categories. I'm confident Ryan will fit in well as we further our investment in both people and infrastructure to drive our next chapter of growth.”
Ryan Govender, added:
“I’m excited to begin working with Daemmon and his colleagues at Treatt, a business which has made extraordinary stride over recent years and has so much potential for the future. With a brand new HQ and a growing team and some fantastic global customers, I’m looking forward to getting started”
The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13 in relation to the appointment.